Team Leader (DSP)

Prof. Dr. Michael Wolff
Prof. Dr. Michael Wolff
Phone: +49 391 67 546 76
Fax: +49 391 6110 588
Room: G25-114

Researcher

Pavel Marichal-Gallardo, M. Sc.
Pavel Marichal-Gallardo, M. Sc.
Phone: +49 391 67 546 79
Fax: +49 391 6110 500
Room: G25-118

A purification platform for viral vaccines & gene therapy vectors

Header image 1543224064

A purification platform for viral vaccines & gene therapy vectors

Motivation

Vaccines are considered among the most successful achievements of modern science. Historically made of mostly crude preparations by today’s standards, these products have become more complex as their manufacturing processes have evolved.

The wide range of existing viruses, their production methods, and the emergence of new public health threats make it extremely difficult to homogenize viral vaccine manufacturing. Viruses need to be isolated from complex mixtures and purified (downstream processing) to extremely high standards.

Current methods used in virus downstream processing, however, have to be tailored to each particular virus species and are commonly extremely expensive, time consuming, and result in high product losses.

These challenges are also true for gene therapy, in which huge amounts of viruses are needed to administer a treatment. The high cost of gene therapies, on the range of several hundred thousand dollars, is partially due to the highly ineffective production & purification methods used nowadays. It is estimated that demand for gene therapy vectors outstrips its supply by a factor of 5.

There is a clear need for platform approaches for virus downstream processing. These urgently needed methods should be inexpensive, robust, give high product recoveries, be fully scalable for commercial production, and at best, be tweaked as little as possible for different viruses and processes in order to homogenize virus purification & accelerate process development.

Aim of the project

Our main goal is to develop a one-for-all solution for purifying viruses produced in cell culture.

Using a low-cost stationary phase, e.g., unmodified cellulose, we capture & purify virus particles by steric exclusion chromatography (SXC). In SXC, the crude sample containing the target species is mixed with polyethylene glycol (PEG) and the product is captured without a direct chemical interaction on the non-reactive hydrophilic surface. The purified viruses are then recovered by reducing the PEG concentration in the mobile phase. Selectivity in SXC is strongly influenced by the target species’ size.

This single-use platform chromatography method can be used to purify a wide range of virus’ size and kinds using a very narrow range of operational parameters with extremely high recoveries (>95%). The same conditions are used to purify different strains of a single virus class, making it extremely powerful compared to other techniques.

Fig. 1: Membrane-based steric exclusion chromatography (SXC) of influenza virus. Zoom Image

Fig. 1: Membrane-based steric exclusion chromatography (SXC) of influenza virus.

References

Marichal-Gallardo, P.; Pieler, M.; Wolff, M. W.; Reichl, U.: Steric exclusion chromatography for purification of cell culture-derived influenza A virus using regenerated cellulose membranes and polyethylene glycol. Journal of Chromatography A 1483 (3), pp. 110 - 119 (2017)

Patents

Wolff M, Pieler M, Marichal-Gallardo P, Reichl U.
Method for the separation of virus compositions including depletion and purification thereof.
 
loading content
Go to Editor View